Phase 4 Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with cancer (either early-stage requiring additional treatment after surgery, or cancer that has spread) and your doctor plans to start you on a chemotherapy drug called 5-FU or Capecitabine.
- You have already had a specific genetic test (called a DPYD test) done by an approved laboratory, and your results are available before you start chemotherapy.
- Your DPYD genetic test shows either one copy of a gene variation (called a heterozygote), OR your DPYD gene results came back completely normal — both groups may be eligible for different parts of the study.
- You are well enough to carry out some light activity or self-care, based on a standard health assessment scale (confirm with trial site).
- You may have cancer that can or cannot be measured on scans — both are allowed.
Who may not be able to join:
- Your doctor has decided that 5-FU or Capecitabine chemotherapy is not safe or appropriate for you.
- Your DPYD genetic test shows two copies of gene variations (meaning both copies of the gene are affected), as this makes these chemotherapy drugs too risky for you.
- You are pregnant.
- You are under 18 years old (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Howard S. Hochster, MD, Study Principal Investigator
Phone: 732-253-5618
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
incidence of severe fluoropyrimidine-related toxicities (Grade 3-5)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.